Local Institution

Samara 443095

0 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndromes, Atrial Fibrillation, Atrial Flutter, Bipolar Disorder, Chronic Hepatitis B, Deep Vein Thrombosis, Hepatitis C Virus, Hepatitis C Virus (HCV), Melanoma, Pulmonary Embolism, Type 2 Diabetes Mellitus, Venous Thrombosis

Studies at this site

• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart — Completed
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma — Completed
• Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes — Completed
• Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma — Completed
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Study of Aripiprazole in Patients With Acute Bipolar Mania — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C — Withdrawn before enrolling